4. A method according to claim 1 wherein the bone resorption inhibiting polyphosphonate has a dose at which mineralization inhibition is observed which is greater than about 10 times the LED for bone resorption inhibition, and is administered daily in an amount of from about 0.25.times.LED to about 10.times.LED.
16. A method according to claim 15 wherein the bone resorption inhibiting polyphosphonates, and daily dosage ranges, are selected from the group consisting of:
Ethane-1-hydroxy-1,1-diphosphonic acid: from about 0.25 mg P/kg to about 2.5 mg P/kg;
Dichloromethane diphosphonic acid: from about 0.12 mg P/kg to about 1.25 mg P/kg;
Propane-3-amino-1-hydroxy-1,1-diphosphonic acid: from about 0.025 mg P/kg to about 0.25 mg P/kg;
Butane-4-amino-1-hydroxy-1,1-diphosphonic acid: from about 0.0025 mg P/kg to about 0.025 mg P/kg;
Hexane-6-amino-1-hydroxy-1,1-diphosphonic acid: from about 0.025 mg P/kg to about 0.25 mg P/kg;
2-(2-pyridyl-ethane-1,1-diphosphonic acid: from about 0.0025 mg P/kg to about 0.025 mg P/kg;
2-(2-pyridyl)-1-hydroxy-ethane-1,1-diphosphonic acid: from about 0.00025 mg P/kg to about 0.0025 mg P/kg; and/or Hexahydroindan-2,2-diphosphonic acid: from about 0.25 mg P/kg to about 2.5 mg P/kg;
and their pharmaceutically-acceptable salts and esters.
21. A method according to claim 17 wherein each cycle comprises: (a) a period of about 14 days during which EHDP, or its pharmaceutically-acceptable salts or esters, is administered daily in an amount of about 1.25 mg P/kg; followed by (b) a rest period of about 84 days.
